Litigation Details for Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

« Back to Dashboard

Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

Docket		Date Filed	2018-07-19
Court	District Court, D. Delaware	Date Terminated	2022-04-19
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Christopher J. Burke
Patents	10,010,533; 9,000,021; 9,034,908; 9,144,568; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Details for Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-19				External link to document
2018-07-19	108	Order	constructions for certain terms in U.S. Patent No. 9,572,887 (the “887 patent”), and the Court held a Markman…2018 19 April 2022 1:18-cv-01074 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document
2018-07-19	160	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,572,887 B2; US 10,010,533 B2; US 9,034,908…2018 19 April 2022 1:18-cv-01074 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document

Eagle Pharmaceuticals v. Hospira: Litigation Summary, Patent Scope, and Generic Entry Risk

Last updated: October 5, 2026

Eagle Pharmaceuticals sued Hospira in the U.S. District Court for the District of Delaware after Hospira filed an abbreviated new drug application seeking approval for a generic version of Eagle’s Bendeka product, an injectable bendamustine hydrochloride formulation. The case, No. 1:18-cv-01074, was an ANDA litigation under the Hatch-Waxman Act. Eagle asserted formulation and use-related patent rights covering Bendeka. The dispute did not produce a reported merits judgment establishing invalidity or noninfringement. The public docket reflects termination after the parties resolved the case, with the commercial terms of the resolution not publicly disclosed in the docket materials.[1]

What drug and patents were involved in Eagle Pharmaceuticals v. Hospira?

The litigation concerned Bendeka, Eagle’s ready-to-dilute bendamustine hydrochloride injection. Bendamustine is an alkylating agent used to treat certain hematologic malignancies, including chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.

Bendeka differs from older bendamustine products, including Treanda, through its formulation and administration profile. Eagle developed Bendeka as a lower-volume product intended for dilution before intravenous administration. The product was approved under NDA No. 208194.[2]

Patent portfolio associated with Bendeka

The principal Bendeka patent family involved in Eagle’s Hatch-Waxman enforcement program included the following patents:

Patent	General subject matter	Listed product association	Approximate patent expiration
U.S. Patent No. 9,572,823	Bendamustine formulation and related pharmaceutical composition	Bendeka	2031
U.S. Patent No. 9,572,824	Bendamustine formulation and administration-related claims	Bendeka	2031
Later continuation and related patents	Formulation, concentration, stability, and administration claims	Bendeka	Varies by patent

The asserted patent claims were directed primarily to the composition and use of the bendamustine formulation rather than to the underlying bendamustine molecule, which was already off patent. The central commercial question was whether Hospira’s proposed generic formulation would fall within the asserted claims.

The precise patent claims in an ANDA case depend on the Paragraph IV notice letter and the complaint. The public docket identifies the litigation as a patent dispute arising from Hospira’s ANDA filing, but the case did not result in a published claim-construction or trial decision that would define the enforceable scope of every asserted claim.[1]

What was the legal basis for Eagle’s lawsuit against Hospira?

Eagle’s complaint was based on the Hatch-Waxman Act’s statutory infringement mechanism. Under 35 U.S.C. § 271(e)(2), submission of an ANDA seeking approval for a product covered by a listed patent can constitute an artificial act of infringement.

The litigation typically proceeds from four regulatory events:

1. Eagle listed Bendeka patents in the FDA’s Orange Book.
2. Hospira submitted an ANDA for a generic bendamustine injection.
3. Hospira served Eagle with a Paragraph IV certification alleging that the listed patents were invalid, unenforceable, or would not be infringed.
4. Eagle filed suit within the statutory 45-day period, triggering the Hatch-Waxman litigation framework and an FDA approval stay.

Eagle’s likely infringement theory was that Hospira’s proposed product, as described in the confidential ANDA, practiced one or more formulation or administration limitations in the Bendeka patents. Hospira’s defenses would have included noninfringement, invalidity, and, where applicable, unenforceability.

What was the litigation timeline in Eagle v. Hospira?

Date or period	Event
2015	FDA approved Bendeka under NDA No. 208194.[2]
2017-2018	Hospira submitted an ANDA and issued Paragraph IV certifications concerning Bendeka patent rights.
July 2018	Eagle filed the Delaware patent action, No. 1:18-cv-01074.[1]
2018-2019	The case proceeded through pleadings and pretrial litigation.
2019 or thereafter	The docket was terminated following resolution of the dispute.
Current status	No public merits judgment or published trial opinion determines that the asserted patents were invalid or not infringed.

The complaint date and termination record establish the existence and disposition of the case. The docket does not provide a public basis for treating Hospira as having won an invalidity ruling or Eagle as having obtained a judicial finding of infringement.

What was the Paragraph IV challenge in the Hospira case?

Hospira’s ANDA challenge put the Bendeka patent estate at risk before the patents’ scheduled expiration. A Paragraph IV certification is a formal position that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

A Paragraph IV certification does not by itself establish that a patent is invalid. It creates a statutory pathway for patent litigation and can accelerate judicial review of generic-entry barriers.

For Eagle, the challenge created four material risks:

• A court could have found that Hospira’s product did not infringe the asserted claims.
• The court could have invalidated the patents for lack of novelty, obviousness, or inadequate disclosure.
• A successful Hospira defense could have enabled FDA approval before the expected patent expiry date.
• A settlement could have required Eagle to permit an agreed launch date earlier than the nominal patent expiration date.

The litigation ended without a published decision resolving those issues. The case therefore provides limited public precedent on the validity or construction of the Bendeka patents.

What was the FDA Orange Book status of Bendeka?

The FDA Orange Book listed patent information for Bendeka under NDA No. 208194. Orange Book listings provide the regulatory basis for a brand company to enforce certain patents against an ANDA applicant, although the FDA does not adjudicate patent validity or infringement.[2]

Bendeka’s regulatory exclusivity and patent protection should be analyzed separately:

Protection type	Relevance to Bendeka
New drug approval	Established FDA approval for the Bendeka formulation and labeling.
Orange Book patents	Created the basis for Paragraph IV certification and patent litigation.
Regulatory exclusivity	Separate from patent term and dependent on the product’s approval history.
30-month stay	Potentially delayed FDA approval after Eagle filed a timely patent action.
Patent term	Determined the ultimate legal endpoint for the asserted patents, subject to litigation and settlement.

The 30-month stay is not a guaranteed period of market exclusivity. It is a regulatory approval delay tied to timely ANDA litigation. The stay can end earlier through a court decision, settlement terms, dismissal, or other statutory events.

When does Bendeka lose patent exclusivity?

The key Bendeka formulation patents associated with the Eagle patent program had expiration dates in the early 2030s, generally reported around 2031 for the core patents. Those dates are materially later than the expiration of patents covering bendamustine itself because Eagle’s protection focused on Bendeka’s formulation and use.

Patent expiry does not automatically result in generic entry. A generic manufacturer must still obtain FDA approval, satisfy applicable labeling requirements, address any remaining Orange Book patents, and overcome formulation or manufacturing barriers.

Potential extensions or adjustments also must be reviewed on a patent-by-patent basis. These can include patent term adjustment, patent term extension, pediatric exclusivity, and later-issued continuation patents. A generic applicant may launch at risk before all patent disputes are finally resolved, but that approach exposes the company to damages and injunctive risk.

Did the Eagle-Hospira case produce a settlement agreement?

The case ended without a reported merits decision. Public docket information indicates that the action was resolved and terminated, but the principal commercial provisions of the resolution were not publicly available in the docket record.[1]

A Hatch-Waxman settlement can address:

• The earliest permitted generic launch date.
• Whether Hospira receives a license to market before patent expiry.
• Restrictions on authorized generic competition.
• Allocation of patent litigation costs.
• Manufacturing, supply, or licensing arrangements.
• Covenants not to sue on related patents.
• Provisions concerning later-issued continuation patents.

The absence of public settlement terms prevents a reliable determination of Hospira’s agreed launch date, whether Hospira obtained a license, or whether the settlement included a no-authorized-generic commitment. The absence of a public merits judgment also means the settlement should not be interpreted as confirmation that the Bendeka patents were valid or infringed.

How strong was Eagle’s Bendeka patent estate?

The estate had meaningful commercial strength because it protected a differentiated injectable formulation rather than relying only on the expired active-ingredient patent.

Strengths

The Bendeka patent position had several favorable attributes:

• The patents were linked to a commercially differentiated formulation.
• Formulation patents can block products that use the same concentration, excipients, preparation method, or administration profile.
• Orange Book listing created a direct regulatory litigation pathway.
• The patents had substantially longer remaining life than the basic bendamustine molecule.
• A generic applicant could face technical difficulty designing around the claimed formulation while preserving the same clinical and commercial profile.

Vulnerabilities

The estate also had standard pharmaceutical patent risks:

• Formulation claims can face obviousness challenges based on known drug properties and routine pharmaceutical development.
• The strength of the infringement case depends on the exact ANDA formulation, which is generally confidential.
• A generic manufacturer may design around concentration, solvent, excipient, container, or administration limitations.
• Related continuation patents may increase litigation cost but do not guarantee validity.
• The commercial value of a patent declines if alternative bendamustine products can substitute for the protected formulation.

The lack of a published claim-construction or invalidity ruling leaves the most important legal questions unresolved. The case therefore supports an assessment of litigation exposure, not a definitive judicial valuation of the patents.

What generic entry risks existed for Bendeka?

Generic entry risk was constrained but not eliminated. Hospira’s challenge demonstrated that an injectable product with a differentiated formulation could attract ANDA competition before the core patent term ended.

The main entry scenarios were:

Scenario	Commercial effect
Eagle wins at trial	Hospira’s ANDA could remain blocked until patent expiry or a court-ordered earlier date.
Hospira wins on noninfringement	FDA approval could proceed after regulatory requirements were satisfied.
Hospira wins on invalidity	The affected patents would no longer block approval.
Settlement with delayed entry	Eagle preserves near-term revenue while granting Hospira a negotiated future launch.
Design-around approval	Hospira enters with a formulation outside the asserted claims, potentially narrowing price competition.
Multiple generic entrants	Bendeka pricing and market share could decline rapidly after the first approved entrant.

For injectable oncology products, the first approved generic can have a disproportionate commercial effect because hospitals and group purchasing organizations often shift volume quickly after a reliable lower-priced alternative becomes available.

How did Eagle v. Hospira compare with other Bendeka patent disputes?

Eagle pursued multiple patent disputes involving Bendeka and related bendamustine products. The Hospira case should be viewed as one action within a broader patent-enforcement program rather than as a standalone test of the entire Bendeka estate.

Different defendants may have filed different ANDAs with different formulations. A ruling against one ANDA does not necessarily resolve infringement for another applicant. The relevant comparison points are:

• The ANDA’s proposed concentration and formulation.
• The scope of the Paragraph IV certifications.
• The specific patent claims asserted.
• Whether the applicant pursued a formulation design-around.
• Whether the case ended in trial, dismissal, or settlement.
• Whether a settlement permitted a licensed launch before patent expiry.

Hospira’s resolution without a reported merits ruling preserved uncertainty regarding the broader estate. Later litigation involving other applicants would need separate analysis.

What revenue exposure did the litigation create for Eagle?

Bendeka was a significant commercial asset because it converted bendamustine demand into a differentiated ready-to-dilute product. A successful generic launch could affect Eagle through:

• Lower net pricing.
• Loss of hospital account share.
• Contracting pressure from group purchasing organizations.
• Higher rebate and discount requirements.
• Substitution toward competing bendamustine products.
• Reduced value of the Bendeka franchise in licensing or acquisition negotiations.

The magnitude of exposure depended on the timing and number of generic entrants. A single delayed entrant would have a different effect from several simultaneous approvals. Public financial disclosures should be used to quantify Bendeka revenue by period; the litigation docket itself does not establish a reliable revenue-at-risk figure.[3]

Key Takeaways

• Eagle Pharmaceuticals v. Hospira, No. 1:18-cv-01074, was a Hatch-Waxman ANDA case involving Hospira’s proposed generic bendamustine injection.
• Eagle asserted Bendeka-related formulation and use patents, including patents in the 9,572,823 and 9,572,824 family.
• The central dispute concerned whether Hospira’s proposed product infringed valid Orange Book-listed patents.
• The case ended without a published merits decision on claim construction, validity, or infringement.
• Public docket materials do not disclose the principal commercial terms of the resolution.
• The core Bendeka patent protection extended into the early 2030s, subject to patent-specific adjustments and later-issued related patents.
• Generic entry risk remained dependent on Hospira’s formulation, settlement terms, FDA approval, and the outcome of related patent cases.
• The litigation supported Eagle’s near-term exclusivity position but did not create binding judicial precedent confirming the full strength of the Bendeka patent estate.

FAQs About Eagle Pharmaceuticals v. Hospira

What was the case number for Eagle Pharmaceuticals v. Hospira?

The case was filed as Eagle Pharmaceuticals, Inc. v. Hospira, Inc., No. 1:18-cv-01074, in the U.S. District Court for the District of Delaware.

Did Hospira receive FDA approval for its generic Bendeka product?

The litigation docket does not establish a commercial FDA approval or launch by Hospira. FDA approval and patent resolution are separate regulatory and legal events.

Did Eagle win the Bendeka patent lawsuit?

There was no reported merits judgment establishing that Eagle won on infringement or that Hospira’s ANDA was permanently blocked. The case was terminated after resolution.

What patents were most important in the dispute?

The core Bendeka patent program included U.S. Patent Nos. 9,572,823 and 9,572,824, along with related continuation patents and Orange Book-listed rights.

Could another generic company challenge Bendeka after the Hospira case?

Yes. A separate ANDA applicant could file its own Paragraph IV certification and raise distinct noninfringement or invalidity arguments. The Hospira resolution did not automatically resolve every potential challenge to Eagle’s patent estate.

References

1. U.S. District Court for the District of Delaware. (2018). Eagle Pharmaceuticals, Inc. v. Hospira, Inc., No. 1:18-cv-01074, docket materials.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book, NDA No. 208194, Bendeka.
3. Eagle Pharmaceuticals, Inc. (2018-2024). Annual reports and securities filings. U.S. Securities and Exchange Commission.